Obstructive Sleep Apnea and Atrial Arrhythmogenesis

Mathias Hohl, Benedikt Linz, Michael Böhm and Dominik Linz*

Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Germany

Abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with relevant morbidity and mortality. Besides hypertension, valvular disease and cardiomyopathy, mainly ischemic and dilated, also other conditions like obesity, alcohol abuse, genetic factors and obstructive sleep apnea (OSA) are discussed to contribute to the progression from paroxysmal to persistent AF. The prevalence of OSA among patients with AF is 40-50%. OSA is characterized by periodic or complete cessation of effective breathing during sleep due to obstruction of the upper airways. Obstructive respiratory events result in acute intrathoracic pressure swings and profound changes in blood gases together leading to atrial stretch and acute sympatho-vagal dysbalance resulting in acute apnea related to electrophysiological and hemodynamic alterations. Additionally, repetitive obstructive events in patients with OSA may lead to sympathetic and neurohumoral activation and subsequent structural and functional changes in the atrium creating an arrhythmogenic substrate for AF in the long run.

This review focuses on the acute and chronic effects of negative thoracic pressure swings, changes in blood pressure and sympatho-vagal dysbalance induced by obstructive respiratory events on atrial electrophysiology and atrial structure in patients with obstructive sleep apnea.

Keywords: Animal experiment, atrial electrophysiology, atrial fibrillation, continuous positive airway pressure, obstructive sleep apnea, renal denervation.

1. INTRODUCTION

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with relevant morbidity and mortality [1]. Different classical risk factors for AF are hypertension, valvular disease and cardiomyopathy, mainly ischemic and dilated. Interestingly, also obesity, alcohol abuse, genetic factors and inflammation have been discussed as additional risk factors for AF [2]. Another condition, which is associated with a high prevalence of AF is obstructive sleep apnea (OSA) [3-5].

In this review, we will describe the pathophysiology of obstructive apneas in OSA potentially influencing atrial structure and electrophysiology and discuss studies investigating the role of different mechanisms on the development of a substrate for AF in OSA.

2. CLINIC OF OSA

A high prevalence of sleep disordered breathing can be found in young patients with both paroxysmal and persistent AF with preserved LV function (62% vs. 38% in patients without AF) [6]. However, the prevalence of daytime symptoms like excessive daytime sleepiness in OSA patients with AF is rare [7]. Therefore, the prevalence of OSA in AF patients may be even underestimated. Gami et al. [5] showed that the severity of OSA is a strong predictor of incident AF in individuals younger than 65 years. Additionally, a prospective analysis by Kanagala et al. [4] demonstrated that patients with OSA have a higher recurrence rate of AF after initial successful cardioversion than patients without OSA. Treatment with continuous positive airway pressure (CPAP) reduced the recurrence rate in OSA patients. Patients with OSA have a higher risk of AF recurrence after catheter ablation than those without OSA and effective treatment of OSA by CPAP improved catheter ablation success rates [8]. AF patients with severe OSA show a lower response rate to antiarrhythmic drug therapy than those with milder forms of OSA [9].

3. PATHOPHYSIOLOGY OF OSA

OSA is characterized by periodic or complete cessation of effective breathing during sleep due to occlusion of the upper airways. An apnea-hypopnea index (AHI) higher than 30 apneas per hour is considered severe OSA. Obstructive apneas caused by the collapse of the upper airway during sleep result in intrathoracic pressure swings provoking myocardial stretch of the heart chambers and lead to changes in transmural pressure gradients, particularly affecting the thinwalled atria [10]. Additionally, obstructive respiratory events induce intermittent apnea-associated hypoxaemia and hypercapnia, leading to sympathetic activation and subsequent intraaapneic and postapneic hemodynamic fluctuations.

Interestingly, in OSA, paroxysms of AF were found to be nocturnal and, at least partly, temporally related to respiratory obstructive events [11, 12]. This temporal link between sleep disordered breathing and the occurrence of AF sug-
suggests that the trigger for AF may be mainly caused by acute changes during apneas and not by chronic remodeling processes in the atria alone [13]. Acute factors directly associated with obstructive respiratory events like intrathoracic pressure changes, changes in blood gases and sympatho-vagal dysbalance may contribute importantly to the occurrence of AF in OSA (Fig. 1).

3.1. Acute Effects of Obstructive Respiratory Events on Atrial Arrhythmogenesis

**Intrathoracic pressure changes:** Obstructed inspirations generate wide fluctuations in intrathoracic pressure, resulting in changes in cardiac transmural pressure, which in turn lead to atrial stretch. Negative tracheal pressures reaching down to -80 to -100 mbar were observed in OSA patients [10, 11]. Tracheal occlusion with applied negative tracheal pressure at -80 mbar resulted in a negative right atrial pressure of -16 mbar and a negative intrathoracic pressure of -65 mbar in a pig model for OSA [14]. This suggests an increase in atrial transmural pressure gradients, which results in atrial distension. Comparable intrathoracic pressure changes and alterations in atrial dimensions were observed during repetitive Mueller maneuvers in humans (attempted inspiration against the obstructed upper airways) [15].

Acute atrial dilation caused by fluctuations in thoracic pressure may result in arrhythmogenic atrial electrophysiological alterations. In isolated Langendorff-perfused rabbit hearts, atrial dilation has been shown to shorten atrial refractoriness [16], slow conduction and increase the amount of intra-atrial conduction blocks [17]. Shortened atrial refractoriness together with lower conduction velocity and increased heterogeneity in local conduction increases the excitabile gap, potentially resulting in increased AF-susceptibility [18]. In a pig model for OSA, application of negative tracheal pressure during tracheal occlusion -but not tracheal occlusion without applied negative tracheal pressure- reproducibly and reversibly shortened the atrial refractory period and strongly enhanced the inducibility of AF [14] (Fig. 2). These acute electrophysiological changes were reversible within 2 minutes after the release of the tracheal occlusion and were mainly mediated by sympatho-vagal imbalance, since they could be influenced by atropine, bilateral vagotomy or beta-receptor blockade [14, 19, 20]. Besides pronounced shortening in atrial refractoriness, obstructive respiratory events also resulted in increased occurrence of spontaneous premature atrial contractions, representing potent triggers for spontaneous AF-episodes in a pig model for OSA [21]. Arrhythmogenic electrophysiological changes were also observed in a rat model for obesity and OSA, which were partly prevented by combined autonomic blockade [22]. Of note, clinically used antiarrhythmic drugs like amiodarone or sotalol were not able to suppress the acute shortening in atrial refractoriness induced by applied negative thoracic pressure in the above mentioned pig model for OSA [20]. In accordance with this finding, Monahan et al. [9] demonstrated “that patients with severe OSA show a lower response rate to antiar-

---

**Fig. (1).** Effects of different conditions during acute (see Chapter 3.1) and chronic (see Chapter 3.2) obstructive respiratory events on atrial electrophysiology, atrial substrates and triggers of atrial fibrillation.
rhythmic drug therapy for AF than those with milder forms of OSA. Interestingly, nonresponders to antiarrhythmic drugs had higher apnea-hypopnea indexes than responders" [9]. However, “minimum oxygen saturation did not differ between the 2 groups” [9]. This suggests that not hypoxia but the obstructive respiratory events, preferably negative thoracic pressure, seem to be important for AF recurrence, limiting antiarrhythmic drugs efficacy in patients with OSA.

**Changes in blood gases:** Hypoxemia, hypercapnia and acidosis are invariably linked with obstructive apneas as occurring in OSA [10, 11]. “The magnitude of nocturnal oxygen desaturation, which is an important consequence of OSA, is an independent risk factor for incident AF.” [5] The electrophysiological effects of isolated hypoxia or hypercapnia were investigated in a sheep model with continuous ventilation under autonomic blockade [23]. Isolated hypercapnia resulted in atrial effective refractory period (AERP)-prolongation. AERP “rapidly returned to baseline, but recovery of conduction was delayed about 2 hours following equalization of hypercapnia. AF vulnerability was reduced during hypercapnia (with increased AERP) but increased significantly with subsequent return to eucapnia (when AERP normalized but conduction time remained disturbed), suggesting that differential recovery of AERP and conduction might be responsible for increased vulnerability to AF” [23]. In superfused rabbit atria, hypoxia caused a transient prolongation and an increase in heterogeneity of refractory periods. Additionally, hypoxia caused depressed conduction velocity and a marked increase in inhomogeneity in conduction both leading to increased vulnerability of the atrium for reentrant arrhythmias [24]. In isolated rabbit pulmonary vein preparations, hypoxia followed by reoxygenation induced pulmonary vein burst firings [25]. However, in a pig model for OSA [14] and in a rat model for obesity and OSA [22], changes in blood gases alone were insufficient to promote AF.

**Sympatho-vagal dysbalance:** Direct recordings of muscle sympathetic nerve activity showed increased sympathetic activation during apneic episodes in OSA patients [11] or in apnea divers [26]. Severe bradycardia and atrioventricular conduction disturbances together with the arousal reaction that limits the apnea duration, characterized by pronounced activation of the sympathetic system and pronounced blood pressure rises due to vasoconstriction and tachycardia, are frequently seen in OSA and suggest sympatho-vagal dysbalance [27, 28]. Forced inspiration-induced acute atrial distension causes an arrhythmogenic atrial electrical remodeling in a rat model for obesity and OSA, which was partly prevented by combined autonomic blockade [22]. Another indicator of pronounced autonomic activation during apnea has been provided by a dog model for central apnea [29]. Inducibility of AF could be attenuated by the ablation of the ganglionated plexi at the right pulmonary artery or by combined pharmacological neurohumoral blockade [29]. In a pig model, nega-
Obstructive Sleep Apnea and Atrial Arrhythmogenesis

3.1. Short Term Obstructive Apneas and Atrial Arrhythmogenesis

Obstructive apneas lead to pronounced shortening of atrial refractoriness thereby perpetuating AF. These electrophysiological changes were mainly mediated by sympatho-vagal dysbalance, since they could be influenced by atropine, bilateral vagotomy or beta-receptor blockade [14, 19-21]. In this pig model, the effect of modulation of sympathetic nervous system by renal sympathetic denervation (RDN) was investigated. RDN is a strategy to modulate sympathetic nervous system and has been shown to reduce muscle sympathetic nerve activity in patients with therapy resistant hypertension [30], suggesting a reduction of central sympathetic drive. Compared to beta-blocker treatment, RDN resulted in a more pronounced attenuation of AERP-shortening induced by negative thoracic pressure, which might explain the superior antiarrhythmic effect of RDN compared to beta-blocker therapy in this animal model [19] (Fig. 3). Additionally, RDN has also been shown to reduce OSA-severity in hypertensive patients as well as it reduces blood pressure [31].

3.2. Longterm OSA and Atrial Structural Remodeling

In patients, longterm OSA has been shown to be associated with significant atrial remodeling characterized by "atrial enlargement, local conduction disturbances and longer sinus node recovery" [32], atrial electromechanical delay and left atrial dysfunction [33].

Several mechanisms have been considered to cause OSA-related myocardial damage including systemic inflammation, neurohumoral activation, chronic atrial dilation by repetitive changes in intrathoracic pressure and multiple comorbidities like obesity and hypertension:

- **Inflammation and neurohumoral activation**: OSA has been shown to be associated with elevations of circulating markers of inflammation [34, 35]. C-reactive protein is associated with vascular inflammation and its serum concentration correlates with AF stability, predict postoperative AF and failure of AF ablation [2].

  Neurohumoral activation, namely the circulating renin angiotensin aldosterone system (RAAS) together with increased oxidative stress, has been shown in OSA patients, which may underlie atrial structural and electrical remodeling in OSA [36, 37]. The RAAS has been shown to play a relevant role for the development of a structural atrial remodeling under different pathophysiological conditions [18]. In a pig model for OSA, RAAS activation was mainly driven by increased sympathetic activation, as it was almost completely attenuated by renal sympathetic denervation [21, 38] (Fig. 4).

- **Effect of hypertension and obesity on structural remodeling**: OSA is considered an etiological factor in the development of hypertension and in the evolution of drug resistant hypertension [39, 40]. In a sheep model, chronically elevated blood pressure was associated with significant atrial electrical and structural remodeling characterized by local conduction disturbances, shortening of atrial wavelength, and increased occurrence of AF, atrial myocyte hypertrophy and myolysis, increased atrial collagen and apoptosis [41]. In another sheep model with induced "one-kidney, one-clip" hypertension, hypertension was associated with early and progressive changes in atrial remodeling [42]. In spontaneously hypertensive rats hypertension was associated with the development of a substrate for atrial tachyarrhythmia “in-

---

**Fig. (3).** Representative atrial multiple action potential (MAP) recordings during AERP-measurements before and after RDN or atenolol in a pig model for OSA. Percent of OSA-maneuvers with inducible atrial fibrillation (AF) and the effect of either atenolol or RDN. (Hypertension 2012; 60: 172-8.).
volving left atrial fibrosis without changes in the atrial effective refractory period” [43]. Longterm hypertension is associated with increased afterload leading to chronic atrial dilation. Longterm atrial dilation during chronic atrioventricular block in the goat caused “intra-atrial conduction defects and a higher contribution of anatomically defined re-entrant circuits” leading to increased AF-susceptibility [44].

Obesity and the metabolic syndrome, both prevalent in OSA patients, may be associated with the development of AF by systemic changes related to these conditions [45]. “There is a 3-8% higher risk of new AF-onset with each unit increase in body mass index, and this association is independent of other cardiovascular risk factors like lipid levels, blood pressure or diabetes” [45]. Pericardial fat is associated with occurrence of AF, persistence of AF, left atrial enlargement, and bad outcomes of AF ablation [46]. Additionally, obesity results in progressive atrial structural and electrical remodeling. In sheep, following a high-calorie diet, obesity was associated with atrial electrostructural remodeling. “With progressive obesity, there were changes in atrial size, conduction, histology, and expression of profibrotic mediators. These changes were associated with spontaneous and more persistent AF” [47].

4. TREATMENT OPTIONS OF ATRIAL FIBRILLATION IN PATIENTS WITH OSA

The data reviewed herein suggest that effective prevention of obstructive respiratory events may result in less AF in patients with OSA. Accordingly, in a case report, treatment with CPAP in an OSA patient with severe metabolic syndrome resulted in lower recurrence of symptomatic AF after electrical cardioversion, lowered high blood pressure and improved metabolic conditions, which were drug resistant at baseline [48]. More importantly, the initiation of a specific antiarrhythmic therapy could be prevented in this patient [48]. These antiarrhythmic effects of CPAP therapy are also confirmed in several clinical studies (see chapter 2) [8, 9, 49]. However, whether rate or rhythm control strategy should be aspirated in OSA-patients despite the prevention of obstructive respiratory events by CPAP is unknown and deserved further clinical trials.

5. SUMMARY

The substrate for AF in OSA seems to be more complex compared to other conditions associated with AF. In addition to the development of a structural remodeling, acute electrophysiological changes during obstructive respiratory events caused by acute changes in blood gases, breathing associated fluctuations in intrathoracic pressure and activation of autonomic system may contribute critically to the development of an arrhythmogenic substrate. This highly arrhythmogenic substrate, characterized by the combination of permanent increased atrial size and the presence of conduction disturbances and intraapneic arrhythmogenic electrophysiological alterations likely contributes to increased recurrence rate of AF following cardioversion or catheter ablation. OSA-associated factors should be considered during the development of future antiarrhythmic pharmacologic and interventional treatment strategies for AF.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.
ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Kirchhof P, Bax J, Blomstrom-Lundqvist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference “research perspectives in AF”. Eur Heart J 2009; 30: 2969-77.

[2] Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrilation: causes of ‘not-so-lone atrial fibrillation’. Europace 2008; 10: 686-73.

[3] Johnson KG, Johnson DC. Obstructive sleep apnea is a risk factor for stroke and atrial fibrillation. Chest 2010; 138: 239.

[4] Kanagal R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 2003; 107: 2589-94.

[5] Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007; 49: 565-71.

[6] Stevenson IH, Teichtahl H, Cunnington D, Ciavraella S, Gordon I, Kalman JM. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J 2008; 29: 1662-9.

[7] Albuquerque FN, Calvin AD, Sert Kuniyoshi FH, et al. Sleep-disordered breathing and excessive daytime sleepiness in patients with atrial fibrillation. Chest 2012; 141: 967-73.

[8] Patel D, Mohanty P, Di Biase L, et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. J Am Coll Cardiol 2010; 57: 119-27.

[9] Monahan K, Brewer J, Wang L, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol 2012; 110: 369-72.

[10] Kasi T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiological and therapeutic implications. J Am Coll Cardiol 2011; 57: 119-27.

[11] Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 2004; 79: 1036-46.

[12] Monahan K, Storfer-Isser A, Mehra R, et al. Triggering of nocturnal arrhythmias by sleep apnea, atrial fibrillation, and heart failure. Am J Respir Crit Care Med 2006; 174: 498-505.

[13] Kohler M, Strading JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7: 677-85.

[14] Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea. Heart Rhythm 2011; 8: 1933-9.

[15] Linz D, Mahfoud F, Schotten U, et al. Renal sympathetic denervation suppresses postprandial blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 2012; 60: 172-8.

[16] Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea. Heart Rhythm 2011; 8: 1933-9.

[17] Linz D, Hohl M, Nickel A, et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension 2013; 62: 767-74.

[18] Iwasaki YK, Shi Y, Benito B, et al. Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm 2012; 9: 1409-16.

[19] Stevenson IH, Roberts-Thomson KC, Kistler PM, et al. Atrial electrophysiology is altered by acute hypercapnia but not hypoxemia: implications for promotion of atrial fibrillation in pulmonary disease and sleep apnea. Heart Rhythm 2010; 7: 1263-70.

[20] Lammers WJ, Kirchhof C, Bonke FI, Allessie MA. Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol 1992; 262: H47-55.

[21] Lin YK, Lai MS, Chen YC, et al. Hypoxia and reoxygeynation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 2012; 122: 121-32.

[22] Heusser K, Dzamoni G, Breskovic T, et al. Sympathetic and cardiovascular responses to glossopharyngeal insufflation in trained apnea divers. J Appl Physiol 2010; 109: 1728-35.

[23] Linz D, Ukena C, Mahfoud F, Neuberger HR, Böhm M. Atrial autonomic innervation: a target for interventional antiarrhythmic therapy? J Am Coll Cardiol 2014; 63: 215-24.

[24] Linz D, van Hunnik A, Ukena C, et al. Renal denervation: effects on atrial electrophysiology and arrhythmias. Clin Res Cardiol 2014 Mar 29. [Epub ahead of print]

[25] Ghias M, Scherlag BJ, Lu Z, et al. The role of ganglionic plexi in apnea-related atrial fibrillation. J Am Coll Cardiol 2009; 54: 2075-83.

[26] Hering D, Lambert EA, Marusic P, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013; 61: 457-64.

[27] Witkowski A, Prebiza A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glyceric acid in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 59-65.

[28] Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: Implications for atrial fibrillation. Heart Rhythm 2011; 9: 321-7.

[29] Yamgor J, Yetkin O, Cansel M, et al. Association between sleep apnea, atrial fibrillation, and heart failure. Am J Hypertens. 2003; 16: 274-43.

[30] Orba L, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. Effects of sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003; 94: 179-84.

[31] Shamsuzzaman AS, Winnick M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-4.

[32] Møller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003; 16: 274-80.

[33] Mancuso M, Bonanni E, LoGerfo A, et al. Oxidative stress biomarkers in patients with untreated obstructive sleep apnea syndrome. Sleep Med 2012; 13: 632-6.

[34] Linz D, Mahfoud F, Linz B, et al. Effect of Obstructive Respiratory Events on Blood Pressure and Renal Perfusion in a Pig Model for Sleep Apnea. Am J Hypertens 2014 Mar 12. [Epub ahead of print]

[35] Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-84.

[36] Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001; 19: 2271-7.

[37] Kistler PM, Sanders P, Dodic M, et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006; 27: 3045-56.

[38] Lau DH, Mackenzie L, Kelly DJ, et al. Development of atrial fibrillation: evidence of progressive atrial remodeling with electrical and structural correlate in a conscious chronically instrumented ovine model. Heart Rhythm 2010; 7: 1282-90.

[39] Choisy SC, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachycardia in spontaneously hypertensive rat hearts. Hypertension 2007; 49: 498-505.

[40] Neuberger HR, Schotten U, Blauw Y, et al. Chronic atrial dilatation, electrical remodeling, and atrial fibrillation in the goat. J Am Coll Cardiol 2006; 47: 644-53.

[41] Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166: 2322-8.
[46] Wong CX, Abed HS, Molaei P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011; 57: 1745-51.

[47] Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation. Heart Rhythm 2013; 10: 90-100.

[48] Linz D, Ukena C, Neuberger HR. Treatment of obstructive sleep apnoea improves metabolic conditions and prevents initiation of antiarrhythmic therapy in a patient with atrial fibrillation. Europace 2014; 16: 245.

[49] Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace 2014 Apr 2. [Epub ahead of print].

Received: April 22, 2014
Revised: May 22, 2014
Accepted: May 23, 2014